Pharma-Biotech Licensing Deals — Stopgap Option or Way of the Future? — Frost & Sullivan Web Conference

LONDON, August 26, 2010 - 2009 and 2010 have seen some of the biggest mergers, acquisitions and
licensing activities the pharmaceutical industry has undergone in a very long
time. In light of dwindling pipeline products, impending patent expirations
for several blockbuster drugs, tight budgets and cost cuts due to the
recession, several major pharmaceutical companies are looking at licensing
promising drug compounds from biotech or other pharmaceutical companies to
remain competitive in the market.

    (Logo: photos.prnewswire.com/prnh/20081117/FSLOGO)
    (Logo: www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

In response to these developments, Frost & Sullivan has organised a
complimentary web conference, entitled Pharma-Biotech Licensing Deals -
Stopgap Option or Way of the Future?, to take place on Thursday, 2nd
September 2010, at 2 p.m. BST. Research Analyst, Ms. Swetha Shantikumar, will
give an analysis of licensing trends by deal value, geographic region,
therapeutic area and stage of drug development.

"Option-based deals are a leading choice for the large pharmas to hedge
financial risk in tough economic times, while exploiting opportunities to
license promising drug candidates in early stages of clinical development,"
observes Shantikumar. "This will typically yield better return-on-investments
in a less competitive environment".

This web conference will benefit top management in pharmaceutical and
biotechnology companies, venture capital and private equity firms as wells as
angel investors by providing an analysis of emerging trends and future
forecasts in the pharma-biotech licensing world.

To participate in this complimentary briefing, please email Katja Feick
at katja.feick@frost.com with your full contact details. Upon receipt of the
above information, a registration link will be e-mailed to you. You may also
register to receive a recorded version of the briefing at anytime by
submitting the aforementioned contact details.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to
accelerate growth and achieve best-in-class positions in growth, innovation
and leadership. The company's Growth Partnership Service provides the CEO and
the CEO's Growth Team with disciplined research and best-practice models to
drive the generation, evaluation, and implementation of powerful growth
strategies. Frost & Sullivan leverages over 45 years of experience in
partnering with Global 1000 companies, emerging businesses and the investment
community from 40 offices on six continents. To join our Growth Partnership,
please visit www.frost.com.

    Contact:
    Katja Feick
    Corporate Communications - Europe
    P: +49-(0)-69-7703343
    E: katja.feick@frost.com
    www.frost.com
    Twitter: twitter.com/frost_sullivan

Katja Feick, Corporate Communications - Europe, Frost & Sullivan, +49-(0)-69-7703343, katja.feick at frost.com